Anitoa Systems, a medical device startup since 2013 with headquarters in Sunnyvale, California, develops a series of highly-integrated molecular testing devices for medical, agriculture, food safety, animal testing, animal health, and environmental monitoring markets.
Leveraging its innovative engineering talents, Antioa is also applying its proprietary CMOS bio-optical molecular sensor with complimentary microfluidics to enable compact, field-portable nucleic-acid-test (NAT) and immunoassay platforms.
By replacing the traditional bulky and expensive photon-multiplier tube (PMT) and CCD-based optical sub-systems, Anitoa’s ultra-low-light CMOS sensor technology enables a new generation of ultra-compact molecular testing platforms targeting many forms of infectious diseases and cardio-vascular diseases.
Anitoa’s mission is to provide doctors and physicians a solution to perform rapid, yet precise diagnostics at point-of-care, instead of waiting for days and weeks to get the results from a centralized lab. Thus they can respond quickly with life-saving treatments, such as targeted antibiotics; and slow the spread of drug-resistant bacteria and viruses.